Coherent receives ISO 13485 certification for Goettingen facility

Article

Coherent Inc. has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany.

Santa Clara, Calif., Sept. 11, 2009 — Coherent Inc. (Santa Clara, CA) (Nasdaq: COHR) has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany. ISO 13485 is an international standard that defines the requirements of comprehensive quality management systems for the design, development, production, customer service and assembly of medical devices. ISO 13485 also specifies protocols for adherence to customer requirements and product improvement within the European regulatory framework for medical devices.

“Achieving ISO 13485 certification benefits all customers who integrate Coherent’s excimer laser products into their surgical systems for eye correction,” notes Heiner Felder, Quality Manager for Medical Products. “The Goettingen certification provides Coherent’s medical customer with expanded capabilities and supplements the existing ISO 13485 certification of the Munich facility. We have now successfully integrated and synchronized all our quality systems for excimer lasers within Coherent.”

Founded in 1966, Coherent, Inc. is a Russell 2000 Index company and a world leader in providing laser-based solutions to the commercial and scientific research markets. Please direct any questions to Heiner Felder, Quality Manager for Medical Products at +49 89 5892746 10. For more information about Coherent, including product and financial updates, visit our website at:
www.coherent.com/excimer

Contact details
Petra Wallenta, PR Manager Europe
+49 89 5892746 25
petra.wallenta@coherent.com

Heiner Felder
+49 89 5892746 10
heiner.felder@coherent.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.